ESMO presentations highlight advances in kidney cancer, melanoma, lung cancer

Fact checked byMindy Valcarcel, MS

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

Healio presents the following updates from ESMO that may be relevant to your practice.

Patients who received the cabozantinib regimen — Data derived from Choueiri TK, et al. Abstract LBA8. Presented at: European Society for Medical Oncology Congress; Sept. 9-13, 2022; Paris.

1. The addition of cabozantinib (Cabometyx, Exelixis) to nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) conferred a significant PFS benefit among patients with advanced renal cell carcinoma. Read more.

2. Neoadjuvant cemiplimab (Libtayo; Regeneron Pharmaceuticals, Sanofi) induced pathologic complete response among a majority of patients with resectable cutaneous squamous cell carcinoma. Read more.

3. An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types. Read more.

4. Exposure to increased concentrations of airborne particulate matter appeared associated with increased risk for EGFR-mutated non-small cell lung cancer among never-smokers. Read more.

5. A novel multicancer early detection blood test identified a common signal for more than 50 cancer types and predicted where the signal originated in the body among individuals with undiagnosed cancer. Read more.

6. A single infusion of tumor-infiltrating lymphocytes more than doubled PFS, OS and complete response rates compared with ipilimumab among patients with advanced, unresectable melanoma. Read more.

7. Two cycles of neoadjuvant nivolumab plus low-dose ipilimumab induced durable pathologic responses among patients with mismatch repair-deficient colon cancer. Read more.

8. The addition of pembrolizumab (Keytruda, Merck) to chemoradiotherapy demonstrated a trend toward longer EFS among patients with locally advanced head and neck squamous cell carcinoma. Read more.

To read comprehensive coverage of this year’s ESMO Congress on Healio, click here.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Coverage

European Society for Medical Oncology Congress

Read more

ESMO presentations highlight advances in kidney cancer, melanoma, lung cancer

Related Content